Mustang Bio

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy $MBIO $FBIO https://t.co/gMMZkCHIg7

Mustang Bio announces its expansion into #autoimmunediseases with MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy. A Phase 1 trial is expected to initiate in the fourth quarter of this year to demonstrate clinical proof-of-concept. $MBIO Learn more here: https://bit.ly/4azqUGS

Mustang Bio reports full-year 2023 financial results and recent corporate highlights. $MBIO Read more here: https://bit.ly/3Vdj7Kk

Phase 1 clinical data were published in @NatureMedicine that demonstrated the promising safety and clinical activity of Mustang Bio’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including #glioblastoma. $MBIO Learn more here:  https://bit.ly/3TeNAVQ

#DYK one out every 10 Americans is living with a rare disease? This #RareDiseaseDay, learn more about Mustang's pipeline and its treatments for rare diseases. https://bit.ly/3Ij0flf #XSCID #BubbleBoyDisease #WaldenstromMacroglobulinemia #GBM $MBIO

#DYK Waldenstrom Macroglobulinemia (WM) is a rare #bloodcancer that originates from malignant B-cells and there is no FDA-approved therapy or standard of care in the third-line setting? There are about 1,400 new patients per year in the U.S. who are diagnosed with the disease.    This #RareDiseaseDay, learn more about #WM and Mustang Bio’s ongoing MB-106 Phase 1/2 trial here: https://bit.ly/49Ku9KW #CD20-targetedCAR T-cell #WaldenstromMacroglobulinemia $MBIO 

#DYK X-Linked Severe Combined Immunodeficiency (XSCID), also commonly known as #BubbleBoyDisease, is a rare mutation in the interleukin 2 receptor gamma (IL2RG) gene that makes a newborn immunocompromised? There are about 30-40 new patients per year in the U.S. who are diagnosed with the disease and without treatment, most patients do not live past the age of one. This #RareDiseaseDay, learn more Mustang Bio’s MB-117 and MB-217 gene therapies to treat XSCID here: https://bit.ly/49Ku9KW #XSCID #BubbleBoyDisease $MBIO

#DYK recurrent glioblastoma (GBM) is a rare and aggressive #braincancer that impacts approximately 12,000 patients in the US annually? Mustang is developing MB-109, a CAR-T cell therapy and oncolytic virus combination, to potentially treat recurrent GBM more effectively. This #RareDiseaseDay, learn more here: https://bit.ly/49Ku9KW  #glioblastoma #GBM #braincancer #CAR-T $MBIO

Get ready for #RareDiseaseDay on February 29. One out of every 10 Americans is living with a rare disease.    Learn more about the rare diseases that Mustang Bio is developing treatments for at MustangBio.com and check out the NORD site to see how you can #ShowYourStripes in support of the 300 million people with rare diseases and disabilities worldwide. https://bit.ly/3uGgFkv $MBIO

Reminder: Mustang Bio’s Robert Sexton, VP, Program & Alliance Leadership, will speak at the Reuters Events Pharma exclusive webinar, Communicate Proven Potentials in Cell & Gene Therapy: Champion Data-Driven Value Proposition, this morning at 10a.m. ET. $MBIO $FBIO For more details: https://bit.ly/3Hv9MVZ